Market research
ARCT Arcturus Therapeutics Holdings Inc
NASDAQ USD Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 382M
- P/E ratio
- Not available
- Analyst target
- 20.2
- Dividend yield
- Not available
- Beta
- 2.27
Profile
Company facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- US03969T1097
- Market cap
- 382M
- P/E ratio
- Not available
- Analyst target
- 20.2
- Dividend yield
- Not available
- Beta
- 2.27
About
About Arcturus Therapeutics Holdings Inc
Arcturus Therapeutics Holdings Inc., a messenger RNA medicines company, focuses on the development of liver and respiratory rare disease therapeutics. Its technology platforms include STARR, a self-amplifying mRNA technology platform, and LUNAR, a lipid-mediated delivery system. The company also develops ARCT-032 (LUNAR-CF), an mRNA therapeutic candidate for cystic fibrosis that is in Phase 2 clinical development; and ARCT-810 (LUNAR-OTC), which is in Phase 2 clinical development to address ornithine transcarbamylase (OTC) deficiency. In addition, it develops KOSTAIVE, a self-amplifying RNA vaccine for COVID-19; ARCT-2138 (LUNAR-FLU), which is in Phase1 clinical trial for the treatment of seasonal influenza; and ARCT-2304 (LUNAR-H5N1) that is in Phase1 clinical trial for the treatment of Pandemic Influenza. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the ARCT discussion.
5 years, 4 months ago
Arcturus Therapeutics Holdings Inc is currently in a long term downtrend where the price is trading 40.0% below its 200 day moving average.
From a valuation standpoint, the stock is 93.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 89.6.
Arcturus Therapeutics Holdings Inc's total revenue sank by 24.6% to $2M since the same quarter in the previous year.
Its net income has dropped by 183.0% to $-31M since the same quarter in the previous year.
Finally, its free cash flow grew by 6.7% to $-7M since the same quarter in the previous year.
Based on the above factors, Arcturus Therapeutics Holdings Inc gets an overall score of 2/5.